Moreau, P., & Goldschmidt, H. (2017). Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia, 31(1), . https://doi.org/10.1038/leu.2016.186
Chicago-Zitierstil (17. Ausg.)Moreau, Philippe, und Hartmut Goldschmidt. "Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in the Phase 3 ENDEAVOR Study." Leukemia 31, no. 1 (2017). https://doi.org/10.1038/leu.2016.186.
MLA-Zitierstil (9. Ausg.)Moreau, Philippe, und Hartmut Goldschmidt. "Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in the Phase 3 ENDEAVOR Study." Leukemia, vol. 31, no. 1, 2017, https://doi.org/10.1038/leu.2016.186.